The Morbidity, Mortality, and Costs Associated with Clostridium difficile Infection

Infectious Disease Clinics of North America

Volumn 29, Issue 1, 2015, Pages 123-134

  Kwon, Jennie H ^a   Olsen, Margaret A ^a   Dubberke, Erik R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Costs; Morbidity; Mortality

Indexed keywords

BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COMORBIDITY; DISEASE SEVERITY; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH SURVEY; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL COST; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MORBIDITY; MORTALITY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHYSICAL EXAMINATION; PROPENSITY SCORE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; STAPHYLOCOCCUS AUREUS; ACUTE DISEASE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; ECONOMICS; EPIDEMIC; INTESTINAL DISEASES; MICROBIOLOGY; RISK FACTOR;

ANTIINFECTIVE AGENT;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DISEASE OUTBREAKS; HOSPITAL COSTS; HUMANS; INTESTINAL DISEASES; RISK FACTORS;

EID: 84922822670     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.11.003     Document Type: Review

References (49)

1. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235:363-372.
2. Tabak Y.P., Zilberberg M.D., Johannes R.S., et al. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol 2013, 34:588-596.
3. Dubberke E.R., Butler A.M., Reske K.A., et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008, 14:1031-1038.
4. Miller M.A., Hyland M., Ofner-Agostini M., et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002, 23:137-140.
5. Loo V.G., Poirier L., Miller M.A., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353:2442-2449.
6. Gravel D., Miller M., Simor A., et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009, 48:568-576.
7. Dubberke E.R., Reske K.A., Olsen M.A., et al. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008, 46:497-504.
8. Stewart D.B., Hollenbeak C.S. Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level. JGastrointest Surg 2011, 15:1548-1555.
9. Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. NEngl J Med 2014, 370:1198-1208.
10. Miller B.A., Chen L.F., Sexton D.J., et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011, 32:387-390.
11. Pepin J., Valiquette L., Gagnon S., et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007, 102:2781-2788.
12. Muto C.A., Pokrywka M., Shutt K., et al. Alarge outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
13. Dudukgian H., Sie E., Gonzalez-Ruiz C., et al. C. difficile colitis-predictors of fatal outcome. JGastrointest Surg 2010, 14:315-322.
14. Al-Abed Y.A., Gray E.A., Rothnie N.D. Outcomes of emergency colectomy for fulminant Clostridium difficile colitis. Surgeon 2010, 8:330-333.
15. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
16. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353:2433-2441.
17. Kasper A.M., Nyazee H.A., Yokoe D.S., et al. Amulticenter study of Clostridium difficile infection-related colectomy, 2000-2006. Infect Control Hosp Epidemiol 2012, 33:470-476.
18. Gash K., Brown E., Pullyblank A. Emergency subtotal colectomy for fulminant Clostridium difficile colitis - is a surgical solution considered for all patients?. Ann R Coll Surg Engl 2010, 92:56-60.
19. Rodriguez-Pardo D., Almirante B., Bartolome R.M., et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. JClin Microbiol 2013, 51:1465-1473.
20. Halabi W.J., Nguyen V.Q., Carmichael J.C., et al. Clostridium Difficile Colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. JAm Coll Surg 2013, 217:802-812.
21. See I., Mu Y., Cohen J., et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014, 58:1394-1400.
22. Dallas K.B., Condren A., Divino C.M. Life after colectomy for fulminant Clostridium difficile colitis: a 7-year follow up study. Am J Surg 2014, 207:533-539.
23. Garey K.W., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. JHosp Infect 2008, 70:298-304.
24. McFarland L.V., Surawicz C.M., Rubin M.S., et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999, 20:43-49.
25. Fekety R., McFarland L.V., Surawicz C.M., et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997, 24:324-333.
26. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597.
27. McFarland L.V. Alternative treatments for Clostridium difficile disease: what really works?. JMed Microbiol 2005, 54:101-111.
28. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
29. Lessa FC. Incidence and insights into C. difficile infection epidemiology [abstract]. ID Week 2012. Available at: . https://idsa.confex.com/idsa/2012/webprogram/Paper33395.html.
30. Elixhauser A., Steiner C., Gould C. Readmissions following hospitalizations with Clostridium difficile infections 2006-2012, Agency for Health Care Policy and Research, Rockville (MD).
31. Micek S.T., Schramm G., Morrow L., et al. Clostridium difficile infection: a multicenter study of epidemiology and outcomes in mechanically ventilated patients. Crit Care Med 2013, 41:1968-1975.
32. Centers for Disease Control and Prevention (CDC) Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1201-1205.
33. Chitnis A.S., Holzbauer S.M., Belflower R.M., et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013, 173:1359-1367.
34. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
35. Pepin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
36. Hall A.J., Curns A.T., McDonald L.C., et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012, 55:216-223.
37. Hoyert D.L., Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012, 61:1-51.
38. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14:929-931.
39. Walk S.T., Micic D., Jain R., et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012, 55:1661-1668.
40. Miller M., Gravel D., Mulvey M., et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010, 50:194-201.
41. Walker A.S., Eyre D.W., Wylie D.H., et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013, 56(11):1589-1600.
42. O'Brien J.A., Lahue B.J., Caro J.J., et al. The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28:1219-1227.
43. Song X., Bartlett J.G., Speck K., et al. Rising economic impact of clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008, 29:823-828.
44. Lipp M.J., Nero D.C., Callahan M.A. Impact of hospital-acquired Clostridium difficile. JGastroenterol Hepatol 2012, 27:1733-1737.
45. Pakyz A., Carroll N.V., Harpe S.E., et al. Economic impact of Clostridium difficile infection in a multihospital cohort of academic health centers. Pharmacotherapy 2011, 31:546-551.
46. Zilberberg M.D., Nathanson B.H., Sadigov S., et al. Epidemiology and outcomes of clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest 2009, 136:752-758.
47. Lagu T., Stefan M.S., Haessler S., et al. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. JHosp Med 2014, 9:411-417.
48. HCUP National Inpatient Sample (NIS) Healthcare Cost and Utilization Project (HCUP) 2012, [report], Agency for Healthcare Research and Quality, Rockville (MD), Available at:, Accessed July 11, 2014. http://www.hcup-us.ahrq.gov/nisoverview.jsp.
49. Dubberke E.R., Schaefer E., Reske K.A., et al. Attributable inpatient costs of recurrent Clostridium difficile infections. Infect Control Hosp Epidemiol 2014, 35:1400-1407.